Erythromycylamine is a macrolide antibiotic and an active metabolite of dirithromycin .1 It is active against a variety of bacteria, including strains of S. pyogenes, S. pneumoniae, L. monocytogenes, and B. pertussis (MICs = 0.06-0.12, 0.06-0.12, 1-2, and 0.015-0.25 μg/ml, respectively). It is also active against 28 clinical isolates of M. avium complex (MAC) isolated from patients with AIDS (MICs = 4-16 μg/ml).2 Erythromycylamine inhibits polylysine and polyproline synthesis in a cell-free assay.3
References
1. Hardy, D.J., Hensey, D.M., Beyer, J.M., et al. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32(11), 1710-1719 (1988).
2. Naik, S., and Ruck, R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob. Agents Chemother. 33(9), 1614-1616 (1989).
3. Matija•evi•, P., Franji•, N., •oki•, S., et al. Erythromycin series. X. Inhibitory activity of several new erythromycin derivatives in cell-free amino acid polymerization systems. Croat. Chem. Acta 53(3), 519-524 (1980).